Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ALCHEMIST Chemo-IO
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT04267848 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ALCHEMIST Chemo-IO (pembrolizumab in resected stage II–IIIB non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ALCHEMIST Chemo-IO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Echocardiography Test; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Observation Activity; Paclitaxel; Pembrolizumab; Pemetrexed Disodium; Questionnaire Administration
- Arms
- Arm A (platinum doublet, observation) · Active comparator
- Arm B (platinum doublet, sequential pembrolizumab) · Experimental
- Arm C (platinum doublet, combination pembrolizumab) · Experimental
- Enrollment
- 1,210 (estimated)
- Primary outcomes
- Disease free survival (DFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 16, 2020
- Primary completion
- Jan 31, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT04267848 · updated Nov 4, 2026
Publications
linked from the registry- Osarogiagbon RU, Cetnar JP, Aljumaily R. Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun;46(3):e518244. doi: 10.1200/EDBK-26-518244. Epub 2026 Jun 23. PubMed 42335416
- Frumm SM, Florez N, Lee JM, Rotow JK, Chaft JE. Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2026 Mar 24;24(4):e267005. doi: 10.6004/jnccn.2026.7005. PubMed 41911908
- Booth A, Hillman S, Laumann K, Zhao YQ, LeBlanc M, Chansky K, Giri S, Dill J, Johnson J, Kelley K, Martin L, Osarogiagbon RU, Morris MJ, Chiang AC, Kozono DE, Blanke CD, Galanis E, Gray JE, Stinchcombe TE, Aljumaily R, Morgensztern D, Mandrekar SJ. PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. J Thorac Oncol. 2026 Jul;21(7):103650. doi: 10.1016/j.jtho.2026.103650. Epub 2026 Feb 24. PubMed 41747891
- Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021 Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21. PubMed 33878954